Latest Glucocorticoids Stories
OPKO Health, Inc. (AMEX:OPK) today announced that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd. (TEVA) to Teva's proprietary formulation of budesonide for the treatment of various inflammatory and allergic conditions of the eye.
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Policing is a psychologically stressful work filled with danger, high demands, ambiguity, human misery and exposure to death, U.S. researchers said. John M.
Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old.
Akorn-Strides has announced the approval of two abbreviated new drug applications for dexamethasone sodium phosphate injection USP, 4mg (base)/mL in 1mL, 5mL, and 30mL vials, and dexamethasone sodium phosphate injection USP, 10mg (base)/mL in 10mL vials.
Something goes awry in the white blood cells of caregivers of the elderly or chronically ill to increase their disease risk, U.S. and Canadian researchers say.
SkyePharma has announced that its development and marketing partner Mundipharma has successfully completed two Phase III clinical studies for the European development program for Flutiform, both of which have shown positive results.
Schering-Plough has announced that Schering-Plough KK, the company's country operation in Japan, has received marketing approval for Nasonex nasal spray 50mcg for the treatment of allergic rhinitis in adult patients.
Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, has received ANDA approval from the FDA for Trandolapril tablets USP 1mg, 2mg and 4mg and will immediately commence marketing and distribution of these products in the US market.
Perrigo Company has filed an abbreviated new drug application for Fluocinonide cream 0.1%, a generic version of Vanos cream 0.1%. The company believes that it is the first to file an abbreviated new drug application (ANDA) with a Paragraph IV certification against Vanos.
- Withering but not falling off, as a blossom that persists on a twig after flowering.